Expert Answers to Questions on PARP Inhibition for Prostate Cancer
In this podcast episode, listen to Charles J. Ryan, MD, and Neal D. Shore, MD, FACS, as they answer questions from a healthcare professional audience on the use of PARP inhibitors and PARP inhibitor combinations for patients with prostate cancer.
Decera Clinical Education Oncology Podcast · Charles J. Ryan MD, Neal D. Shore MD FACS
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Charles J. Ryan, MD, and Neal D. Shore, MD, FACS, answer questions from a healthcare professional audience on topics related to prostate cancer and PARP inhibition including:
- Germline and somatic mutation testing
- Managing adverse events with PARP inhibitors
- Resistance to PARP inhibitors
- Implications of monoallelic vs biallelic BRCA mutations
- ATM mutations and PARP inhibitor sensitivity
Presenters:
Charles J. Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Oncologist
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota
Neal D. Shore, MD, FACS
Director
Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina
Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:
https://bit.ly/2P31ZqF
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.